Bradley Morgan

Bradley Morgan has an extensive and diverse work experience spanning over two decades. Bradley is currently the Managing Director, Healthcare & Life Sciences at Katan Associates International, a position they have held since July 2022. Prior to this role, they served as an Associate at the same company from January 2014 to June 2022.

In August 2022, Bradley became the Chief Business Officer at Harae Dx Corp. Bradley is responsible for leading business operations in this position.

From April 2018 to September 2021, Bradley worked at 7BC.VC as a Venture Partner and Head of China. Bradley played a vital role in developing strategic plans and establishing a network of funds in China.

Before that, at POC Medical Systems, Bradley served as the Vice President, Global Corporate & Business Development from May 2014 to March 2018. Bradley successfully raised equity and venture debt financing and developed business strategies for diagnostic products in Europe, China, and India.

Bradley also held the role of Director of Corporate Strategy and Business Development at OneMedMarket in 2012 and worked as a Proprietary Trader at BAM Capital Management LLC from 2003 to 2008.

In their earlier career, they gained experience as a Senior Financial Analyst at Holliday Fenoglio Fowler, advising on debt placement for commercial real estate transactions. Bradley also worked as a Senior Financial Analyst at General Growth Properties and as a Research Associate at Kannon Consulting.

Bradley started their career as a Derivatives Analyst intern at J.P. Morgan in 1999. Throughout their professional journey, they have accumulated a wealth of knowledge and experience in various industries, including healthcare and life sciences, finance, and real estate.

Bradley Morgan attended Emory University from 1996 to 2000, where they obtained a Bachelor of Arts degree in Economics. Bradley graduated with magna cum laude honors, including thesis honors. Additionally, during their time at Emory, Bradley pursued a second major in English.